Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

Cocrystal Pharma, Inc.

Contributing Author

Recent Articles by Cocrystal Pharma, Inc.

Dec-01	Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference COCP GlobeNewswire
Nov-14	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire
Oct-30	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules COCP GlobeNewswire
Oct-27	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program COCP GlobeNewswire
Oct-02	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference COCP GlobeNewswire
Sep-15	Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules COCP GlobeNewswire
Sep-12	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules COCP GlobeNewswire
Sep-12	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference COCP GlobeNewswire
Sep-08	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment COCP GlobeNewswire
Sep-03	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference COCP GlobeNewswire
Aug-14	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire
Aug-05	Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference COCP GlobeNewswire
Jul-10	Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference COCP GlobeNewswire
Jun-05	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference COCP GlobeNewswire
May-29	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain COCP GlobeNewswire
May-28	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference COCP GlobeNewswire
May-15	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.